Large gap with delayed quotes
|
Last quote
04/27/2026
-
16:29:33
|
Bid
04/27/2026 -
16:29:33
|
Bid Volume |
Ask
04/27/2026 -
16:29:33
|
Ask Volume |
|---|---|---|---|---|
|
511.56
-0.83
(
-0.16% )
|
510.20
|
40 |
513.93
|
40 |
Analysis date: 24.04.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 21.04.2026.
Interest
Very strong
Very strong
Four stars since 21.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 21.04.2026 at a price of 527.69.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 27.03.2026.
4wk Rel Perf
5.85%
5.85%
The four-week dividend-adjusted overperformance versus SP500 is 5.85%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.96%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.07%.
Mkt Cap in $bn
11.75
11.75
With a market capitalization >$8bn, MADRIGAL PHARMACEUTICALS is considered a large-cap stock.
G/PE Ratio
1.83
1.83
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
16.61
16.61
The estimated PE is for the year 2028.
LT Growth
30.41%
30.41%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
20
20
For 1% of index variation, the stock varies on average by 0.20%.
Correlation
0.04
0.04
Stock movements are totally independent of index variations.
Value at Risk
126.74
126.74
The value at risk is estimated at USD 126.74. The risk is therefore 24.74%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
27.07.2018
27.07.2018